Careful design and maintenance of our fragment library is of great importance to the ZoBio lead discovery process. Continuous improvement of our collection relies both on commercial acquisition of new fragments and gaining access to unique and novel compounds…
The ZoBio Fragment Library: Chemically Diverse Starting Points for Drug Discovery
ZoBio strives to provide attractive, validated chemical starting points for your drug discovery projects. To achieve this goal, we have been building and maintaining the ZoBio fragment library since 2003. Our fragment library has been screened against more than 100 targets…
NMR in Target Driven Drug Discovery: Why Not?
NMR is a powerful and information rich tool that can provide critical information at many stages of the pre-clinical drug discovery process.
In a recent publication ZoBio scientists discuss a number of examples…
Mirati and ZoBio Collaborate to Advance Targeted Oncology Programs
Mirati Therapeutics has selected ZoBio to provide fragment-based screening, biophysical compound characterization and structural biology for several oncology targets. In this arrangement, ZoBio screens…